Double-masked, placebo-controlled safety and efficacy trial of diquafosol tetrasodium (INS365) ophthalmic solution for the treatment of dry-eye

Cornea

Volumn 23, Issue 8, 2004, Pages 784-792

  Tauber, Joseph ^a   Davitt, W F ^b   Bokosky, J E ^c   Nichols, K K ^d   Yerxa, B R ^e   Schaberg, A E ^e   LaVange, L M ^e   Mills Wilson, M C ^e   Kellerman, D J ^e  

^a Tauber Eye Center   (United States)

^b Corona Research ^*  (United States)

^c San Diego   (United States)

^d OHIO STATE UNIVERSITY   (United States)

^e MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Artificial tears; Corneal staining; Diquafosol tetrasodium; Dry eye; INS365; Keratoconjunctivitis sicca; P2Y2 receptor agonist

Indexed keywords

DIQUAFOSOL; PLACEBO; PURINE P2Y2 RECEPTOR; PURINERGIC RECEPTOR STIMULATING AGENT;

ADULT; ARTICLE; BURNING SENSATION; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG INSTILLATION; DRUG MECHANISM; DRUG SAFETY; DRUG TOLERABILITY; DRY EYE; EYE DISEASE; EYE PAIN; FEMALE; FOREIGN BODY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; SCHIRMER TEST; SIDE EFFECT; STAINING; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; CONJUNCTIVA; CONTRAST MEDIA; CORNEA; DOUBLE-BLIND METHOD; DRY EYE SYNDROMES; FEMALE; FLUORESCEIN; HUMANS; MALE; MIDDLE AGED; OPHTHALMIC SOLUTIONS; POLYPHOSPHATES; RECEPTORS, PURINERGIC P2; SAFETY; STAINING AND LABELING; TEARS; TREATMENT OUTCOME; URACIL NUCLEOTIDES;

EID: 7444243225     PISSN: 02773740     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.ico.0000133993.14768.a9     Document Type: Article

References (33)

1. Moss SE, Klein R, Klein BE. Prevalence of and risk factors for dry eye syndrome. Arch Ophthalmol. 2000;118:1264-1268.
2. Mathers WD. Why the eye becomes dry: A cornea and lacrimal gland feedback model. CLAO J. 2000;26:159-165.
3. Nelson JD, Helms H, Fiscella R, et al. A new look at dry eye disease and its treatment. Adv Ther. 2000;17:84-93.
4. Schein OD, Muñoz B, Tielsch JM, et al. Prevalence of dry eye among the elderly. Am J Ophthalmol. 1997;124:723-728.
5. Schaumberg DA, Sullivan DA, Dana MR. Epidemiology of dry eyes syndrome. In: Sullivan DA et al, eds. Lacrimal Gland, Tear Film, and Dry Eye Syndromes 3. New York: Kluwer Academic/Plenum Publishers; 2002:989-998.
6. Foulks GN. Challenges and pitfalls in clinical trials of treatments for dry eye. Ocular Surface. 2003;1:20-30.
7. Schaumberg DA, Sullivan DA, Buring JE, et al. Prevalence of dry eye syndrome among US women. Am J Ophthalmol. 2003;136:318-326.
8. Lemp MA. Report of the National Eye Institute/industry workshop on clinical trials in dry eyes. CLAO J. 1995;21:221-232.
9. Baudouin C. The pathology of dry eye. Surv Ophthalmol. 2001;45(Suppl 2): S211-S220.
10. Bron AJ. Diagnosis of dry eye. Surv Ophthalmol. 2001;45(Suppl 2): S221-S226.
11. Nichols KK, Begley CG, Caffery B, et al. Symptoms of ocular irritation in patients diagnosed with dry eye. Optom Vis Sci. 1999;76:838-844.
12. Li Y, Kuang K, Yerxa B, et al. Rabbit conjunctival epithelium transports fluid, and P2Y2 receptor agonists stimulate Cl- and fluid secretion. Am J Physiol Cell Physiol. 2001;281:C595-C602.
13. Wen Q, Li Y, Kuang K, et al. Effects of P2Y2 agonists on lipid secretion by cultured rabbit meibocytes. ARVO Annual Meeting May 2002, 3146 (B130).
14. Fujihara T, Murakami T, Fujita H, et al. Improvement of corneal barrier function by the P2Y2 agonist INS365 in a rat dry eye model. Invest Ophthalmol Vis Sci. 2001;42:96-100.
15. Foulks G, Sall K, Greenberg ME, et al. Phase 2 dose ranging efficacy trial of INS365 ophthalmic solution, a P2Y2 agonist, in patients with dry eye. Invest Ophthalmol Vis Sci. 2001;42:S713 (3839).
16. Schaumberg DA, Buring JE, Sullivan DA, et al. Hormone replacement therapy and dry eye syndrome. JAMA. 2001;286:2114-2119.
17. Chiou AGY, Florakis GJ, Kazim M. Management of conjunctival cicatrizing diseases and severe ocular surface dysfunction. Diagnostic and Surgical Techniques. Surv Ophthalmol. 1999;43:19-46.
18. Goto E, Yagi Y, Matsumoto Y, et al. Impaired functional visual acuity of dry eye patients. Am J Ophthalmol. 2002;133:181-186.
19. Sade de Paiva C, Lindsey JL, Pflugfelder SC. Assessing the severity of keratitis sicca with videokeratoscopic indices. Opthalmology. 2003;110:1102-1109.
20. Tamhane AC, Hochberg Y, Dunett CW. Multiple test procedures for dose finding. Biometrics. 1996;52:21-37.
21. Zeger SL, Liang K-Y. Longitudinal data analysis for discrete and continuous outcomes. Biometrics. 1986;42:121-130.
22. Pflugfelder SC, Jones D, Ji Z, et al. Altered cytokine balance in the tear fluid and conjunctiva of patients with Sjögren's syndrome keratoconjunctivitis sicca. Curr Eye Res. 1999;19:201-211.
23. Nelson JD, Gordon JF. Topical fibronectin in the treatment of keratoconjunctivitis sicca. Am J Ophthalmol. 1992;114:441-447.
24. Sall K, Stevenson OD, Mundorf TK, et al. Two multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. Ophthalmology. 2000;107:631-639.
25. Stevenson D, Tauber J, Reis BL. Efficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease. Ophthalmology. 2000;107:967-974.
26. Afonso AA, Monroy D, Stern ME, et al. Correlation of tear fluorescein clearance and Schirmer test scores with ocular irritation symptoms. Ophthalmology. 1999;106:803-810.
27. Begley C, Chalmers R, Mitchell GL, et al. Characterization of ocular surface symptoms from optometric practices in North America. Cornea. 2001;20:610-618.
28. Schein OD, Tielsch JM, Muñoz B, et al. Relation between signs and symptoms of dry eye in the elderly. Ophthalmology. 1997;104:1395-1401.
29. Begley CG, Chalmers RL, Abetz L, et al. The relationship between habitual patient-reported symptoms and clinical signs among patients with dry eye of varying severity. Invest Ophthalmol Vis Sci. 2003;44:4753-4761.
30. Bandeen-Roche K, Muñoz B, Tielsch JM, et al. Self-reported assessment of dry eye in a population-based setting. Invest Ophthalmol Vis Sci. 1997;38:2469-2475.
31. Gearinger MD, Mah FS, Foulks GN. Correlation of corneal sensitivity with subjective and objective scoring in dry eye patients. Invest Ophthalmol Vis Sci. 2000;41:S273 (1433).
32. Kellerman DJ, Sall KN, Bokosky JE, et al. Diquafosol tetrasodium (INS365) ophthalmic solution is not absorbed systemically in patients with dry eye. Invest Ophthalmol Vis Sci. 2003;3740.
33. Pflugfelder SC, Solomon A, Stern M. The diagnosis and management of dry eye: A twenty-five year review. Cornea. 2000;19:644-649.